🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Solid tumors and ovarian cancer

    phase 1 other active

    1 trial

  2. An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

    AstraZeneca AB

    Breast Cancer

    phase 1 other active

    1 trial

  3. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 160 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subject

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

  4. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 80 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

  5. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  6. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  7. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  8. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Endometrial Cancer

    phase 1 small molecule active

    1 trial

  9. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  10. Atovaquone Oral Suspension

    United Therapeutics Europe Ltd

    Locally Advanced Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  11. BBO-11818

    BridgeBio Oncology Therapeutics

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  12. BBO-8520

    BridgeBio Oncology Therapeutics

    Non-small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  13. BBP-398 with nivolumab

    BridgeBio Oncology Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  14. BDC-3042

    Bolt Biotherapeutics

    Triple Negative Breast Cancer

    phase 1 small molecule terminated

    1 trial

  15. BG-60366

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  16. BG-68501

    BEONE MEDICINES AUS PTY LTD

    Breast Cancer

    phase 1 small molecule active

    1 trial

  17. BG-75202

    BEONE MEDICINES AUS PTY LTD

    Breast Cancer

    phase 1 small molecule active

    1 trial

  18. BGB-21447

    BEONE MEDICINES AUS PTY LTD

    Hormone-receptor-positive Breast Cancer

    phase 1 small molecule active

    1 trial

  19. BGB-B3227

    BEONE MEDICINES AUS PTY LTD

    Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  20. BL-M07D1

    Sichuan Baili Pharmaceutical Co.,

    Breast Cancer

    phase 1 small molecule active

    1 trial

  21. BMS-641988 (AR#2)

    Bristol-Myers Squibb

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  22. BMS-906024

    Bristol-Myers Squibb

    Cancer

    phase 1 small molecule completed

    1 trial

  23. BMS-986148

    Bristol-Myers Squibb

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  24. BPX-601

    Regeneron UK Limited

    Prostate Cancer

    phase 1 gene therapy active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources